Dihexa

Dihexa is a small peptidomimetic compound derived from angiotensin IV (Ang IV), developed by researchers at Washington State University. It acts as an agonist at the hepatocyte growth factor (HGF)/c-Met signaling axis by potentiating HGF activity. In preclinical models, Dihexa enhanced the formation of new synaptic connections (synaptogenesis) in the hippocampus and prefrontal cortex, reversing cognitive deficits in rodent models of Alzheimer's disease. Researchers reported in vitro potency approximately 10 million times greater than BDNF for promoting synaptogenesis — a finding that generated significant interest in the nootropic and longevity research community. Human clinical data does not exist; all evidence is preclinical. The mechanism (HGF/c-Met potentiation driving synaptogenesis) is distinct from other cognitive peptides like Semax or Selank.

Reconstitution

Often used as a transdermal preparation due to poor aqueous solubility. Can be dissolved in DMSO for research use. Oral bioavailability data is limited.